NEW YORK (GenomeWeb) – Baylor Research Institute (BRI) at Dallas and the Translational Genomics Research Institute (TGen) in Phoenix today announced an agreement to collaborate on early detection and treatment of cancers.
BRI and TGen will collaborate on precision medicine for cancer patients by offering liquid biopsies, performing gene sequencing, conducting clinical trials, and creating personalized vaccines.
The partners will concentrate on three research areas: breast and other cancers associated with women's health; abdominal malignancies including pancreatic, colorectal, and liver cancers; and blood cancers including leukemia, lymphoma, and multiple myeloma.
They will provide the precision medicine services across Baylor Scott & White Health's 49 hospitals throughout Texas. Baylor Scott & White Health is non-profit healthcare system that was formed through the 2013 merger of Baylor Health Care System and Scott & White Healthcare.
"We will combine TGen's strengths in genomics and proteomics with BRI's strengths in metabolomics and immune-based approaches, initially focusing on genomic, molecular, and translational research for oncology," Robert Pryor, president, COO, and CMO of Baylor Scott & White Health, said in a statement.
Researchers will work in clinics and labs throughout the Baylor healthcare system as well as TGen facilities in Phoenix and Scottsdale, Arizona. A joint operations program will manage the collaboration from the Charles A. Sammons Cancer Center at the Baylor University Medical Center in Dallas.
The organizations said they will also collaborate in other research areas, such as infectious disease, cardiovascular health, diabetes, neurology, and metabolic disease.
Financial details of the collaboration were not disclosed.
In May 2014, TGen launched a personalized medicine collaboration with George Mason University.